---
title: "688163.SH (688163.SH) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/688163.SH/news.md"
symbol: "688163.SH"
name: "688163.SH"
parent: "https://longbridge.com/zh-CN/quote/688163.SH.md"
datetime: "2026-03-11T08:12:05.907Z"
locales:
  - [en](https://longbridge.com/en/quote/688163.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688163.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688163.SH/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/688163.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688163.SH/news.md)


# 688163.SH (688163.SH) — 相关新闻

### [SHANGHAI SERUM BIO-TECHNOLOGY's net profit attributable to the parent company for the year 2025 is 51.7135 million yuan, a year-on-year increase of 16.76%](https://longbridge.com/zh-CN/news/277006867.md)
*2026-02-26T08:37:13.000Z*
> SHANGHAI SERUM BIO-TECHNOLOGY released its performance preliminary report for 2025, with total operating revenue of 196 

### [SHANGHAI SERUM BIO-TECHNOLOGY released its performance for the first three quarters, with a net profit attributable to the parent company of 64.21 million yuan, a year-on-year increase of 2.01%](https://longbridge.com/zh-CN/news/262868019.md)
*2025-10-27T10:20:03.000Z*
> According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY disclosed its third-quarter report for 2025. The com

### [SHANGHAI SERUM BIO-TECHNOLOGY's revenue slightly increased in the first half of the year, with limited overall market space for its main products | Directly covering the earnings conference](https://longbridge.com/zh-CN/news/257345208.md)
*2025-09-15T10:33:25.000Z*
> SHANGHAI SERUM BIO-TECHNOLOGY achieved revenue of 101 million yuan in the first half of 2023, a year-on-year increase of

### [Zhitong A-share lock-up release overview | September 11](https://longbridge.com/zh-CN/news/256824781.md)
*2025-09-11T01:01:03.000Z*
> On September 11th, a total of 3 listed companies had their restricted shares unlocked, with a total market value of appr

### [SHANGHAI SERUM BIO-TECHNOLOGY released its semi-annual performance, with a net profit attributable to the parent company of 32.98 million yuan, a year-on-year increase of 2.07%](https://longbridge.com/zh-CN/news/254401185.md)
*2025-08-25T09:09:02.000Z*
> According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY disclosed its semi-annual report for 2025. During th

### [SHANGHAI SERUM BIO-TECHNOLOGY: Rabies antiserum has been listed for sale online](https://longbridge.com/zh-CN/news/254392613.md)
*2025-08-25T08:28:27.000Z*
> SHANGHAI SERUM BIO-TECHNOLOGY announced that the company's rabies immune globulin products have recently been listed on 

### [SHANGHAI SERUM BIO-TECHNOLOGY: Has not conducted research related to AIDS vaccines](https://longbridge.com/zh-CN/news/251778517.md)
*2025-08-06T07:51:53.000Z*
> SHANGHAI SERUM BIO-TECHNOLOGY stated on the interactive platform that the company has not conducted any research related

### [](https://longbridge.com/zh-CN/news/243382984.md)
*2025-06-06T05:29:03.000Z*
> The A-share innovative drug concept experienced a volatile rebound, with CSBIO rising over 16% to reach a new historical